Journal article
Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFNg
Stefan Bauer, Jeannette C Oosterwijk-Wakka, Nicole Adrian, Egbert Oosterwijk, Eliane Fischer, Thomas Wueest, Frank Stenner, Angelo Perani, Leonard Cohen, Alexander Knuth, Chaitanya Divgi, Dirk Jaeger, Andrew M Scott, Gerd Ritter, Lloyd J Old, Christoph Renner
INTERNATIONAL JOURNAL OF CANCER | WILEY | Published : 2009
DOI: 10.1002/ijc.24359
Abstract
Immunotherapeutic targeting of G250/Carbonic anhydrase IX (CA-IX) represents a promising strategy for treatment of renal cell carcinoma (RCC). The well characterized human-mouse chimeric G250 (cG250) antibody has been shown in human studies to specifically enrich in CA-IX positive tumors and was chosen as a carrier for site specific delivery of TNF in form of our IgG-TNF-fusion protein (cG250-TNF) to RCC xenografts. Genetically engineered TNF constructs were designed as CH2/CH3 truncated cG250-TNF fusion proteins and eucariotic expression was optimized under serum-free conditions. In-vitro characterization of cG250-TNF comprised biochemical analysis and bioactivity assays, alone and in combi..
View full abstractGrants
Funding Acknowledgements
Grant sponsors: Europrofession c.V.. Wilheim Sander Foundation, University of Zurich, conducted as part of the Atlantic Philanthropies/Ludwig Institute for Cancer Research Clinical Discover, Program.